SCHEMBL6450651

SCHEMBL6450651

Cc1cc2c(cc1-c1cc(/C=C3/SC(=S)NC3=O)ccc1N(C)C)C(C(C)C)=CCC2(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 2/20 0.44
MAX P61244 2/20 0.44
CRHBP P24387 2/20 0.44
CRHR2 Q13324 2/20 0.44
PDE4B Q07343 5/20 0.42
PDE3A Q14432 5/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NAT1 P18440 2/20 0.41
PIM1 P11309 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 2/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
NPC1 O15118 2/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
PTP4A3 O75365 1/20 0.39
DYRK1A Q13627 3/20 0.39
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6450655 1.00 MYC (0.44) MYCMAXCRHBPCRHR2PDE4B
SCHEMBL6449455 0.92 RXRA (0.44) PDE4BPIM1GSK3BPIM3PIM2
SCHEMBL6449457 0.92 RXRA (0.44) PDE4BPIM1GSK3BPIM3PIM2
SCHEMBL6449423 0.86 PDE4B (0.57) MYCMAXPDE4BPDE3AMEN1
SCHEMBL6449424 0.86 PDE4B (0.57) MYCMAXPDE4BPDE3AMEN1
SCHEMBL6451521 0.84 PDE4B (0.42) MYCMAXCRHBPCRHR2PDE4B
SCHEMBL6451524 0.84 PDE4B (0.42) MYCMAXCRHBPCRHR2PDE4B
SCHEMBL6450667 0.82 RXRA (0.34) RXRA
SCHEMBL6448365 0.80 IGF1R (0.47) PDE4BPIM1GAAPIM3PIM2
SCHEMBL6448359 0.80 IGF1R (0.47) PDE4BPIM1GAAPIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038098-A1 Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases INCYTE CORPORATION 2005-02-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038098-A1 Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases HSD17B10, IDH2, INSR MYC 272/4885MAX 3929/4885CRHBP 2901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.